196 results on '"Coulter, Don W."'
Search Results
2. The miR-29 family facilitates the activation of NK-cell immune responses by targeting the B7-H3 immune checkpoint in neuroblastoma
3. SAP30, a novel autophagy regulatory gene in neuroblastoma
4. Unveiling the Potential of Combined BET and HDAC Inhibition in MYC-driven Medulloblastoma Treatment: A Promising Epigenetic Approach
5. The crosstalk between non-coding RNAs and cell-cycle events: A new frontier in cancer therapy
6. SAP30, an oncogenic driver of progression, poor survival, and drug resistance in neuroblastoma
7. Immune checkpoint molecules in neuroblastoma: A clinical perspective
8. The emerging role of non-coding RNAs in the epigenetic regulation of pediatric cancers
9. miR-15a and miR-15b modulate natural killer and CD8+T-cell activation and anti-tumor immune response by targeting PD-L1 in neuroblastoma
10. A novel dual epigenetic approach targeting BET proteins and HDACs in Group 3 (MYC-driven) Medulloblastoma
11. Preliminary preclinical study of Chol-DsiRNA polyplexes formed with PLL[30]-PEG[5K] for the RNAi-based therapy of breast cancer
12. Synergistic efficacy of inhibiting MYCN and mTOR signaling against neuroblastoma
13. FOXJ3, a novel tumor suppressor in neuroblastoma
14. PRMT5 as a Potential Therapeutic Target in MYC-Amplified Medulloblastoma
15. PD-L1, inflammation, non-coding RNAs, and neuroblastoma: Immuno-oncology perspective
16. Long non-coding RNA profiling of pediatric Medulloblastoma
17. Low Motor Dexterity and Significant Behaviors Following Hospitalized Isolation in Children
18. Interactions of Butyrylcholinesterase with Neuroblastoma-associated Oncoproteins
19. Role of protein arginine methyltransferase 5 in group 3 (MYC-driven) Medulloblastoma
20. Effects of novel pyrrolomycin MP1 in MYCN amplified chemoresistant neuroblastoma cell lines alone and combined with temsirolimus
21. STAT3 Inhibition Attenuates MYC Expression by Modulating Co-Activator Recruitment and Suppresses Medulloblastoma Tumor Growth by Augmenting Cisplatin Efficacy In Vivo
22. Data from A Novel Combination Approach Targeting an Enhanced Protein Synthesis Pathway in MYC-driven (Group 3) Medulloblastoma
23. Supplementary Materials and Methods from A Novel Combination Approach Targeting an Enhanced Protein Synthesis Pathway in MYC-driven (Group 3) Medulloblastoma
24. Supplementary Table from A Novel Combination Approach Targeting an Enhanced Protein Synthesis Pathway in MYC-driven (Group 3) Medulloblastoma
25. Figure S1-S9 from A Novel Combination Approach Targeting an Enhanced Protein Synthesis Pathway in MYC-driven (Group 3) Medulloblastoma
26. Abstract 6050: JMJD6 regulates super-enhancer mediated transcriptional dependencies in group 3 medulloblastoma
27. Abstract 2349: SAP30, a novel drug response specific transcription factor in high-risk neuroblastoma
28. SAP30, an oncogenic driver of progression, survival, and drug resistance in high-risk neuroblastoma
29. Additional file 1 of A novel dual epigenetic approach targeting BET proteins and HDACs in Group 3 (MYC-driven) Medulloblastoma
30. Additional file 2 of A novel dual epigenetic approach targeting BET proteins and HDACs in Group 3 (MYC-driven) Medulloblastoma
31. Additional file 3 of A novel dual epigenetic approach targeting BET proteins and HDACs in Group 3 (MYC-driven) Medulloblastoma
32. Direct Comparison of Chol-siRNA Polyplexes and Chol-DsiRNA Polyplexes Targeting STAT3 in a Syngeneic Murine Model of TNBC
33. Histiocytic Neoplasms, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology
34. Multifarious Functions of Butyrylcholinesterase in Neuroblastoma: Impact of BCHE Deletion on the Neuroblastoma Growth In Vitro and In Vivo
35. Direct Comparison of Chol-siRNA Polyplexes and Chol-DsiRNA Polyplexes Targeting STAT3 in a Syngeneic Murine Model of TNBC
36. Additional file 1 of Synergistic efficacy of inhibiting MYCN and mTOR signaling against neuroblastoma
37. Pediatric Hodgkin Lymphoma, Version 3.2021
38. Refractory autoimmune hemolytic anemia after intestinal transplant responding to conversion from a calcineurin to mTOR inhibitor
39. Multifarious Functions of Butyrylcholinesterase in Neuroblastoma: Impact of BCHE Deletion on the Neuroblastoma Growth In Vitro and In Vivo.
40. Parenteral Nutrition—Induced Hypersensitivity in an Adolescent
41. Assessment of Tissue Distribution and Metabolism of MP1, a Novel Pyrrolomycin, in Mice Using a Validated LC-MS/MS Method
42. Naïve Helper T-Cell and Regulatory T- and NK-Cell Subsets Are Associated with Pediatric Chronic Graft-Versus-Host Disease: Results of the ABLE / PBMTC 1202 Study
43. Exosomes secreted under hypoxia enhance stemness in Ewing’s sarcoma through miR-210 delivery
44. Amino Acids Regulate Cisplatin Insensitivity in Neuroblastoma
45. Alpha-Particle Therapy for Multifocal Osteosarcoma: A Hypothesis
46. A Novel Combination Approach Targeting an Enhanced Protein Synthesis Pathway in MYC-driven (Group 3) Medulloblastoma
47. Radiolabeled (R)‐(–)‐5‐iodo‐3′‐O‐[2‐(ε‐guanidinohexanoyl)‐2‐phenylacetyl]‐2′‐deoxyuridine: A new theranostic for neuroblastoma
48. Additional file 3 of Long non-coding RNA profiling of pediatric Medulloblastoma
49. Multifarious Functions of Butyrylcholinesterase in Neuroblastoma: Impact of BCHEDeletion on the Neuroblastoma Growth In Vitro and In Vivo
50. Biological Evaluation of a Potential Anticancer Agent MethylN-[5-(3′-Iodobenzoyl)-1H-Benzimidazol-2-yl]Carbamate
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.